Abstract：
This is the first report of vestibular examinations before and after the successful treatment of vestibular migraine (VM), a common cause of recurrent vertigo, with calcitonin gene-related peptide (CGRP) receptor inhibitor. We evaluated a 42-year-old female with VM and concomitant probable Meniere\'s disease, whose headache and dizziness have improved promptly with the administration of erenumab, a CGRP receptor inhibitor. The sensorineural hearing loss in pure-tone audiometry, dysfunctions shown in vestibular examinations (cervical and ocular vestibular evoked myogenic potentials), and mild endolymphatic hydrops shown in gadolinium-enhanced inner ear magnetic resonance imaging, all in the right ear, revealed no change compared with those observed before treatment. This case suggests that VM may be treated by blocking CGRP in the trigeminal ganglion, which suppresses the effects on the vestibular nucleus; herein, no effects were observed in the inner ear despite the clear amelioration of dizziness.
摘要：
这是前庭性偏头痛（VM）成功治疗前后的前庭检查的第一份报告，复发性眩晕的常见原因,降钙素基因相关肽（CGRP）受体抑制剂。我们评估了一名42岁的女性，患有VM和伴随的可能的梅尼埃病，其头痛和头晕随着erenumab的给药迅速改善，CGRP受体抑制剂。纯音测听中的感觉神经性听力损失，在前庭检查中显示的功能障碍（颈部和眼部前庭诱发的肌源性电位），钆增强内耳磁共振成像显示轻度内淋巴积液，所有在正确的耳朵，与治疗前观察到的相比没有变化。这种情况表明，可以通过阻断三叉神经节的CGRP来治疗VM，抑制对前庭核的影响；在这里，尽管头晕明显改善，但内耳未观察到任何影响。
